The unblinded data from the study shows that Apta-1 has been well tolerated in the given doses. No serious side effects were seen and all participants fulfilled the study. In the additional analyzes that were performed during the study Apta-1 showed signs of having effect on some markers which are important for understanding its mechanism of action. The significance of these findings will be evaluated in the continued preclinical and future clinical studies.

CEO Mikael Lindstam comments:

"I am pleased to say that the preliminary unblinded results confirm what we previously have communicated. While we wait for the final study report we continue to plan for the next step in the clinical development program for Apta-1 based on these insights."

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.